Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Home/Insights/Industry context: microvascular diagnostics

Industry context: microvascular diagnostics

The commercial opportunity is diagnostic — and the obstacle is that the condition is under-diagnosed because testing is not routinely done or reimbursed.

Microcirculation and microvascular function

Where the activity is

Pressure and flow wire systems for invasive coronary function testing, and the software deriving indices from them. Non-invasive perfusion quantification in CMR, PET and CT. Analysis software, including automated quantification.

Therapeutics activity is comparatively limited, in part because existing anti-anginal agents are generic and because stratified trials are only now defining who should receive what.

The reimbursement problem

Coronary function testing adds time and cost to a procedure that would otherwise end when obstructive disease is excluded. Where it is not reimbursed it is not routinely performed, so the condition is not diagnosed, so the evidence base and the market both grow slowly.

This is a recognisable pattern in diagnostics: the diagnostic and the treatment evidence are mutually dependent, and neither develops without the other.

What evidence would change it

Demonstration that testing changes management and improves outcomes or symptom burden — not merely that it identifies abnormality. Health economic evaluation including the cost of the current alternative, which is repeated presentation and repeated investigation of undiagnosed patients.

For readers of claims here

Distinguish analytical validity (does the device measure what it claims), clinical validity (does the measure identify the condition) and clinical utility (does using it improve outcomes). Most diagnostic marketing establishes the first and implies the third.

Diagnostic accuracy studies should be reported to STARD and appraised with QUADAS-2; check the reference standard and whether it was applied to all participants.

In short

What to take from this.

  • Distinguish analytical validity, clinical validity and clinical utility.
  • Diagnostic accuracy studies: STARD for reporting, QUADAS-2 for appraisal.
  • Check whether the reference standard was applied to everyone.

Sources

  • STARD Statement and QUADAS-2
  • Health technology assessment literature on diagnostic evaluation

This page reflects established understanding as at mid-2026 and is not a current-awareness service. Clinical and regulatory positions change; verify anything decision-relevant against a current source.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.